Hemispherx Biopharma to Present at the 15th Annual Rodman & Renshaw Global
Investment Conference in New York City September 8-10th
PHILADELPHIA, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE
MKT:HEB), today announced it will be featured as a presenting company at the
15^th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.
Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at
the Millennium Broadway Hotel in New York City.
Dr. William A. Carter, Chairman and CEO of Hemispherx, will provide an
overview of the Company's business during the live presentation and will be
available to participate in one-on-one meetings with investors who are
registered to attend the conference. Emphasis will include new data on
Hemispherx's platform technologies as they relate to potential treatment
and/or prevention of emerging pandemic viral threats.
If you are an institutional investor, and would like to attend the Company's
presentation, please click on the following link (www.rodm.com) to register
for the Rodman & Renshaw conference. Once your registration is confirmed, you
will be prompted to log into the conference website to request a one-on-one
meeting with the Company.
Event: 15^th Annual Rodman & Renshaw Global Investment Conference
Date: September 9, 2013
Time: 3:40 PM Eastern Time
Location: Room 7.02, 7^th Floor; Millennium Broadway Hotel in New York City
The presentation will be webcast live. To access the webcast, please visit
http://www.hemispherx.net or http://www.wsw.com/webcast/rrshq23/heb. The
webcast replay will remain available for 90 days following the live
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company
engaged in the manufacture and clinical development of new drug entities for
treatment of seriously debilitating disorders. Hemispherx's flagship products
include Alferon N Injection® and the experimental therapeutics Ampligen® and
Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed
for globally important debilitating diseases and disorders of the immune
system, including Chronic Fatigue Syndrome. Hemispherx's platform technology
includes components for potential treatment of various severely debilitating
and life threatening diseases. Because both Ampligen® and Alferon® LDO are
experimental in nature, they are not designated safe and effective by a
regulatory authority for general use and are legally available only through
clinical trials. Hemispherx has patents comprising its core intellectual
property estate and a fully commercialized product (Alferon N Injection®),
approved for sale in the U.S. and Argentina.The Company's Alferon N approval
in Argentina includes the use of Alferon N Injection (under the brand name
"Naturaferon") for use in any patients who fail or become intolerant to
recombinant interferon, including patients with chronic active hepatitis C
infection.The approval for Alferon N in the United States is for the
treatment of refractory or recurrent Condylomata Acuminatain patients 18
years of age or older.The Company wholly owns and exclusively operates a GMP
certified manufacturing facility in the United States for commercial products.
For more information please visit http://www.hemispherx.net.
To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995.Words such as "believes," "potential," "potentially," "possibility,"
"may" and similar expressions are intended to identify forward-looking
statements.The inclusion of forward-looking statements should not be regarded
as a representation by Hemispherx that any of its plans will be
achieved.These forward-looking statements are neither promises nor guarantees
of future performance, and are subject to a variety of risks and
uncertainties, many of which are beyond Hemispherx's control, which could
cause actual results to differ materially from those contemplated in these
forward-looking statements.Examples of such risks and uncertainties include
those set forth in the, above, as well as the risks described in Hemispherx's
filings with the Securities and Exchange Commission, including the most recent
reports on Forms 10-K, 10-Q and 8-K.You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof, and Hemispherx undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise revise or update this
release to reflect events or circumstances after the date hereof.
About Rodman & Renshaw Conferences, LLC
The Rodman & Renshaw Annual Global Investment Conference is an informational
service and networking opportunity for companies and investors. Rodman does
not prepare, review or edit the presentations and other information provided
by each company, and does not take any responsibility for the accuracy or
adequacy of any such information as the basis for any investment decision.
Rodman is not providing any person with any investment advice through their
participation in or attendance of the Conference, nor is Rodman soliciting any
offers to buy or sell any security of any company.
CONTACT: Company/Investor Contact:
Hemispherx Biopharma, Inc.
Press spacebar to pause and continue. Press esc to stop.